Nanovibronix, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
ENvue Medical, Inc. reported a significant decrease in revenue for the second quarter of 2026, alongside an increase in net loss, while also detailing ongoing efforts to secure financing and manage operational challenges.
ENvue Medical, Inc. reported a significant revenue decrease for the first quarter of 2026, primarily due to the market removal of a key product, while also highlighting ongoing liquidity concerns.
NanoVibronix reports increased Q3 2025 revenue driven by the ENvue merger, despite continued operating losses, a going concern warning, and product withdrawal.
NanoVibronix, Inc. reported a significant increase in net loss and declining revenues for Q2 2025, alongside a recent merger, multiple reverse stock splits, and a product withdrawal.
NanoVibronix's Q1 2025 results reflect the impact of the ENvue merger and a reverse stock split, with increased revenue offset by higher operating expenses and a net loss.
NanoVibronix saw a significant increase in revenue year-over-year but continues to experience net losses and faces substantial doubt about its ability to continue as a going concern.
NanoVibronix saw a significant increase in revenue during the second quarter of 2024, but the company's financial statements raise substantial doubt about its ability to continue as a going concern.
NanoVibronix saw a significant increase in revenue during the first quarter of 2024, but faces substantial doubt about its ability to continue as a going concern due to ongoing losses and a potential arbitration payment.